Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene - Concepedia

Concepedia

Publication | Open Access

Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

DOI Full Paper Access

683

Citations

24

References

2004

Year

Silvana Martino, Jane A. Cauley, Elizabeth Barrett‐Connor, Trevor J. Powles, John L. Mershon, Damon Disch, Roberta J. Secrest, Steven R. Cummings

JNCI Journal of the National Cancer Institute

Abstract

The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis. No new safety concerns related to raloxifene therapy were identified during CORE.

References

	Year	Citations

Page 1